IMMUNOPRECISE ANTIBODIES LTD

ImmunoPrecise to Present at the Benchmark Company’s Discovery One-on-One Virtual Video Investor Conference on Thursday December 2, 2021

Retrieved on: 
Wednesday, November 24, 2021
Infectious Diseases, Biotechnology, Pharmaceutical, Health, Benchmark, Conference, Company, TSX, Research, LLC, Antibody, Epitope, NASDAQ, Video game, the Benchmark Company & Discovery One on One Virtual Video Investor Conference 2021., ImmunoPrecise Antibodies Ltd, THE BENCHMARK COMPANY & DISCOVERY ONE ON ONE VIRTUAL VIDEO INVESTOR CONFERENCE 2021., IMMUNOPRECISE ANTIBODIES LTD

IMMUNOPRECISE ANTIBODIES LTD. (the Company or IPA) (NASDAQ: IPA) (TSX VENTURE: IPA) is presenting at the Benchmark Companys Discovery One-on-One Virtual Video Investor Conference.

Key Points: 
  • IMMUNOPRECISE ANTIBODIES LTD. (the Company or IPA) (NASDAQ: IPA) (TSX VENTURE: IPA) is presenting at the Benchmark Companys Discovery One-on-One Virtual Video Investor Conference.
  • About the Benchmark Company & Discovery One on One Virtual Video Investor Conference 2021.
  • The Benchmark Company, LLC, is a diversified financial services firm that offers a full suite of investment banking and institutional brokerage services.
  • Benchmarks Discovery One-on-One Virtual Video Investor Conference will be showcasing dynamic publicly traded micro-cap companies in an intimate conference setting.

Talem Therapeutics Announces Multi-Target Antibody Discovery Research Collaboration With Pierre Fabre

Retrieved on: 
Thursday, October 7, 2021
Oncology, Health, Infectious Diseases, Research, Science, Pharmaceutical, Biotechnology, NASDAQ, Company, Forward-looking statement, Pharmacy, Technology, Therapy, IPA, Derma, Mississippi, Breast, Phrase, Pierre Fabre, Animal, Antibody, Multimedia, Time, TSX Venture Exchange, Melanoma, News, Environment, TSX, Lung cancer, Drug discovery, ISO, Library, Group, National Voluntary Guidelines on Social, Environmental and Economic Responsibilities of Business, Health care, Research, Epitope, Vaccine, Pharmaceutical industry, Pierre Fabre, ImmunoPrecise Antibodies Ltd, Talem Therapeutics LLC, PIERRE FABRE, IMMUNOPRECISE ANTIBODIES LTD, TALEM THERAPEUTICS LLC

IMMUNOPRECISE ANTIBODIES LTD. (the Company or IPA) (NASDAQ: IPA) (TSX VENTURE: IPA) and the Pierre Fabre pharmaceutical group announced today that IPAs subsidiary, Talem Therapeutics LLC (Talem), and Pierre Fabre have entered a multi-year, multi-target research collaboration with the goal to discover and develop therapeutics antibodies for up to nine targets.

Key Points: 
  • IMMUNOPRECISE ANTIBODIES LTD. (the Company or IPA) (NASDAQ: IPA) (TSX VENTURE: IPA) and the Pierre Fabre pharmaceutical group announced today that IPAs subsidiary, Talem Therapeutics LLC (Talem), and Pierre Fabre have entered a multi-year, multi-target research collaboration with the goal to discover and develop therapeutics antibodies for up to nine targets.
  • Its portfolio ranges across several medical franchises and international brands, including Pierre Fabre Oncology, Pierre Fabre Dermatology, Eau Thermale Avne, Klorane, Ducray, Ren Furterer, A-Derma, Naturactive and Pierre Fabre Oral Care.
  • Pierre Fabre is 86%-owned by the Pierre Fabre Foundation, a government-recognized public-interest foundation, and secondarily by its own employees through an international employee stock ownership plan.
  • Forward-looking information contained in this news release include, but are not limited to, statements regarding the potential of the research collaboration with Pierre Fabre and our expectations with respect to that research collaboration and, any license that may be entered into with Pierre Fabre as a result of that research collaboration, and the potential of our other programs or services.